Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 691 to 700 of 1143 total matches.

A New Amphetamine Oral Suspension (Adzenys ER) for ADHD (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 18, 2018  (Issue 1549)
, psychosis, drug dependence, or alcoholism. DRUG INTERACTIONS – Adzenys ER is contraindicated for use ...
The FDA has approved an extended-release oral suspension formulation of amphetamine (Adzenys ER – Neos) for treatment of attention deficit hyperactivity disorder (ADHD) in patients ≥6 years old. The same extended-release amphetamine product is available as an orally disintegrating tablet and is marketed as Adzenys XR-ODT. Another extended-release oral suspension formulation of amphetamine, Dyanavel XR, was approved earlier.
Med Lett Drugs Ther. 2018 Jun 18;60(1549):e106-8 |  Show IntroductionHide Introduction

Comparison Table: Some Nonopioid Analgesics for Pain (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 07, 2022  (Issue 1645)
Drug Interactions May decrease effectiveness of diuretics, beta blockers, ACE inhibitors, and some ...
View the Comparison Table: Some Nonopioid Analgesics for Pain
Med Lett Drugs Ther. 2022 Mar 7;64(1645):e40-3 |  Show IntroductionHide Introduction

Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2013  (Issue 1423)
in animals; no adequate studies in women) for use during pregnancy. DRUG INTERACTIONS — Bedaquiline ...
Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a diarylquinoline antimycobacterial, has been given accelerated approval by the FDA as an orphan drug for use in addition to other drugs for treatment of adults with multidrug-resistant pulmonary tuberculosis (MDR-TB). It is the first drug approved specifically to treat MDR-TB.
Med Lett Drugs Ther. 2013 Aug 19;55(1423):66-8 |  Show IntroductionHide Introduction

A Topical Carbonic Anhydrase Inhibitor For Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Sep 01, 1995  (Issue 956)
well tolerated, but they are absorbed systemically and can cause adverse drug interactions, cardiac ...
Dorzolamide hydrochloride (Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Med Lett Drugs Ther. 1995 Sep 1;37(956):76-7 |  Show IntroductionHide Introduction

Daclatasvir (Daklinza) for HCV Genotype 3 Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015  (Issue 1479)
women. Daclatasvir has been detected in the milk of lactating rats. DRUG INTERACTIONS — Severe ...
The FDA has approved daclatasvir (Daklinza – BMS), an oral direct-acting antiviral drug, for use with sofosbuvir (Sovaldi) for treatment of chronic hepatitis C virus (HCV) genotype 3 infection. Daclatasvir is the first drug approved for this indication that does not require the addition of interferon or ribavirin. It is approved in Japan and Europe in combination with other drugs for treatment of HCV genotypes 1-4.
Med Lett Drugs Ther. 2015 Oct 12;57(1479):142-3 |  Show IntroductionHide Introduction

Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain

   
The Medical Letter on Drugs and Therapeutics • Mar 14, 2016  (Issue 1490)
to an increased incidence of stillbirth. DRUG INTERACTIONS — NSAIDs may decrease the effectiveness of diuretics ...
The FDA has approved Vivlodex (Iroko), a low-dose formulation of the nonsteroidal anti-inflammatory drug meloxicam (Mobic, and generics), for management of osteoarthritis pain. According to the manufacturer, the new formulation aligns with stronger FDA warnings about the cardiovascular risks of NSAIDs and the recommendation to use the lowest possible doses of these drugs.
Med Lett Drugs Ther. 2016 Mar 14;58(1490):35-6 |  Show IntroductionHide Introduction

Panobinostat (Farydak) for Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 17, 2015  (Issue 1475)
. DRUG INTERACTIONS — Panobinostat is a substrate of CYP3A and P-glycoprotein (P-gp) and an inhibitor ...
The FDA has approved panobinostat (Farydak – Novartis), an oral histone deacetylase (HDAC) inhibitor, for use in combination with bortezomib (Velcade) and dexamethasone for treatment of patients with multiple myeloma who have received at least 2 prior therapies including bortezomib and an immunomodulatory drug. It is the first HDAC inhibitor to be approved for this indication.
Med Lett Drugs Ther. 2015 Aug 17;57(1475):e118-9 |  Show IntroductionHide Introduction

Memantine for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2003  (Issue 1165)
The Medical Letter  On Drugs and Therapeutics www.medicalletter.org Published by The Medical ...
Memantine hydrochloride, which has been used to treat dementia in Germany (Axura Merz) since 1982, has become the latest word-of-mouth miracle drug for Alzheimer's disease in the US (G Kolata, NY Times, June 15, 2003). Forest Laboratories has submitted a New Drug Application to the FDA for memantine. This review describes the standard treatment for Alzheimer's Disease, mechanism of action, clinical studies, adverse effects and dosage. Also included are sections on availability of the drug and how some people are obtaining memantine from abroad.
Med Lett Drugs Ther. 2003 Sep 15;45(1165):73-4 |  Show IntroductionHide Introduction

Macitentan (Opsumit) for Pulmonary Arterial Hypertension

   
The Medical Letter on Drugs and Therapeutics • Feb 17, 2014  (Issue 1436)
and prevented during treatment and for one month afterwards. DRUG INTERACTIONS — Strong CYP3A4 inducers ...
The FDA has approved macitentan (ma" si ten' tan; Opsumit – Actelion), for oral treatment of pulmonary arterial hypertension (PAH). Macitentan is the second nonselective endothelin receptor antagonist approved for PAH. It is a derivative of bosentan (Tracleer), which is also manufactured by Actelion, and is scheduled to become available generically in 2015. Riociguat (Adempas), another new drug for this indication, will be reviewed in a future issue. Volibris
Med Lett Drugs Ther. 2014 Feb 17;56(1436):15-6 |  Show IntroductionHide Introduction

Buprenorphine Implants (Probuphine) for Opioid Dependence

   
The Medical Letter on Drugs and Therapeutics • Jul 18, 2016  (Issue 1499)
. DRUG INTERACTIONS — Buprenorphine in any form may interfere with the analgesic efficacy of full opioid ...
The FDA has approved subdermal implants of the partial opioid agonist buprenorphine (Probuphine – Titan) for maintenance treatment of opioid dependence in patients stabilized on low to moderate doses of transmucosal buprenorphine. Probuphine was designed to provide continuous low levels of buprenorphine for 6 months and to safeguard against illicit use of the drug.
Med Lett Drugs Ther. 2016 Jul 18;58(1499):94-5 |  Show IntroductionHide Introduction